Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 6
2004 5
2005 12
2006 15
2007 43
2008 52
2009 78
2010 74
2011 57
2012 89
2013 108
2014 108
2015 109
2016 88
2017 75
2018 92
2019 64
2020 7
Text availability
Article attribute
Article type
Publication date

Search Results

976 results
Results by year
Filters applied: . Clear all
Page 1
Panitumumab in the treatment of colon cancer: A biomarker dilemma.
Scott A, Messersmith WA, Jimeno A, Davies SL. Scott A, et al. Drugs Today (Barc). 2014 Oct;50(10):679-90. doi: 10.1358/dot.2014.50.10.2221787. Drugs Today (Barc). 2014. PMID: 25374966 Review.
Panitumumab for the treatment of metastatic colorectal cancer: a review.
Del Prete M, Giampieri R, Faloppi L, Bianconi M, Bittoni A, Andrikou K, Cascinu S. Del Prete M, et al. Immunotherapy. 2015;7(7):721-38. doi: 10.2217/imt.15.46. Epub 2015 Aug 7. Immunotherapy. 2015. PMID: 26250414 Review.
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer.
Zhao B, Wang L, Qiu H, Zhang M, Sun L, Peng P, Yu Q, Yuan X. Zhao B, et al. Oncotarget. 2017 Jan 17;8(3):3980-4000. doi: 10.18632/oncotarget.14012. Oncotarget. 2017. PMID: 28002810 Free PMC article. Review.
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Carrato A, Abad A, Massuti B, Grávalos C, Escudero P, Longo-Muñoz F, Manzano JL, Gómez A, Safont MJ, Gallego J, García-Paredes B, Pericay C, Dueñas R, Rivera F, Losa F, Valladares-Ayerbes M, González E, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). Carrato A, et al. Eur J Cancer. 2017 Aug;81:191-202. doi: 10.1016/j.ejca.2017.04.024. Epub 2017 Jun 19. Eur J Cancer. 2017. PMID: 28633089 Free article. Clinical Trial.
Panitumumab.
Chua YJ, Cunningham D. Chua YJ, et al. Drugs Today (Barc). 2006 Nov;42(11):711-9. doi: 10.1358/dot.2006.42.11.1032061. Drugs Today (Barc). 2006. PMID: 17171190 Review.
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.
Rivera F, Karthaus M, Hecht JR, Sevilla I, Forget F, Fasola G, Canon JL, Guan X, Demonty G, Schwartzberg LS. Rivera F, et al. Int J Colorectal Dis. 2017 Aug;32(8):1179-1190. doi: 10.1007/s00384-017-2800-1. Epub 2017 Apr 19. Int J Colorectal Dis. 2017. PMID: 28424871 Free PMC article. Clinical Trial.
Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
Boeckx N, Koukakis R, Op de Beeck K, Rolfo C, Van Camp G, Siena S, Tabernero J, Douillard JY, André T, Peeters M. Boeckx N, et al. Ann Oncol. 2017 Aug 1;28(8):1862-1868. doi: 10.1093/annonc/mdx119. Ann Oncol. 2017. PMID: 28449055 Free PMC article.
Panitumumab-Induced Immune Complex Glomerulonephritis.
Izzedine H, Boostandoost H, Mathian A. Izzedine H, et al. Am J Kidney Dis. 2017 Feb;69(2):320-321. doi: 10.1053/j.ajkd.2016.09.011. Epub 2016 Oct 17. Am J Kidney Dis. 2017. PMID: 27765383 No abstract available.
Panitumumab as a possible cause of hematospermia: what is the mechanism?
Karatas F, Sahin S, Imamoglu GI, Altinbas M. Karatas F, et al. Future Oncol. 2015;11(24):3229-31. doi: 10.2217/fon.15.264. Epub 2015 Nov 12. Future Oncol. 2015. PMID: 26562760 No abstract available.
976 results
Jump to page
Feedback